Second of the two phase I bioequivalence trials of once-daily extended release formulation of lorcaserin in healthy adults

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 10 Nov 2016

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

27 Sep 2016 Results assessing pharmacokinetics published in the Clinical Therapeutics.
20 Jul 2016 According to Eisai media release, based on results of this and another phase I trial (CTP 700255707) the US FDA has approved a New Drug Application (NDA) for lorcaserin for chronic weight management.
30 Nov 2015 According to Eisai Inc media release, the US FDA has accepted for filling the New Drug Application (NDA) for extended release lorcaserin based on results of this and another phase I trial (CTP 700255707).

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com